IL105143A - Stable crystalline monohydrates of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo [3.2.1] oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides their preparation and pharmaceutical compositions containing them - Google Patents

Stable crystalline monohydrates of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo [3.2.1] oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides their preparation and pharmaceutical compositions containing them

Info

Publication number: IL105143A
Authority: IL; Israel
Prior art keywords: compound; azabicyclo; dihydro; oxo; endo
Prior art date: 1992-03-26

Application number

IL10514393A

Other languages

English (en)

Original Assignee

Boehringer Ingelheim Italia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-26

Filing date

1993-03-24

Publication date

1996-10-16

1992-03-26 Priority claimed from ITMI920720A external-priority patent/IT1254562B/it

1992-03-26 Priority claimed from ITMI920723A external-priority patent/IT1254565B/it

1993-03-24 Application filed by Boehringer Ingelheim Italia filed Critical Boehringer Ingelheim Italia

1996-10-16 Publication of IL105143A publication Critical patent/IL105143A/en

Links

238000002360 preparation method Methods 0.000 title claims abstract description 17
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
150000004682 monohydrates Chemical class 0.000 title claims abstract description 10
SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 claims abstract description 23
YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 claims abstract description 22
238000000034 method Methods 0.000 claims abstract description 20
230000008569 process Effects 0.000 claims abstract description 12
150000001875 compounds Chemical class 0.000 claims description 119
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
239000013078 crystal Substances 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
239000003125 aqueous solvent Substances 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
-1 oct-3-yl Chemical group 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 1
229910001868 water Inorganic materials 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
239000002775 capsule Substances 0.000 description 24
239000003814 drug Substances 0.000 description 24
229940079593 drug Drugs 0.000 description 24
239000000243 solution Substances 0.000 description 20
238000003801 milling Methods 0.000 description 14
238000003860 storage Methods 0.000 description 14
229910052799 carbon Inorganic materials 0.000 description 13
238000004458 analytical method Methods 0.000 description 11
239000000126 substance Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
230000008901 benefit Effects 0.000 description 9
238000010438 heat treatment Methods 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
238000013112 stability test Methods 0.000 description 8
238000002411 thermogravimetry Methods 0.000 description 8
230000015556 catabolic process Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
238000003795 desorption Methods 0.000 description 7
229920002261 Corn starch Polymers 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
239000007857 degradation product Substances 0.000 description 6
238000000113 differential scanning calorimetry Methods 0.000 description 6
239000008101 lactose Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
239000008120 corn starch Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000012047 saturated solution Substances 0.000 description 5
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
239000008119 colloidal silica Substances 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
238000001914 filtration Methods 0.000 description 4
230000007774 longterm Effects 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000002156 mixing Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000829 suppository Substances 0.000 description 4
238000003828 vacuum filtration Methods 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
239000001828 Gelatine Substances 0.000 description 3
238000004566 IR spectroscopy Methods 0.000 description 3
229920001328 Polyvinylidene chloride Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000005030 aluminium foil Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000012458 free base Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
229910052753 mercury Inorganic materials 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000005033 polyvinylidene chloride Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
238000002459 porosimetry Methods 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000010439 graphite Substances 0.000 description 2
229910002804 graphite Inorganic materials 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000010951 particle size reduction Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
238000004467 single crystal X-ray diffraction Methods 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NRHZAVJNUJCQRL-UHFFFAOYSA-N 4-[4-(4-aminophenyl)piperazin-1-yl]aniline Chemical compound C1=CC(N)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 NRHZAVJNUJCQRL-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000006561 Cluster Headache Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000005280 amorphization Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical group C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000018912 cluster headache syndrome Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000001757 thermogravimetry curve Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

IL10514393A 1992-03-26 1993-03-24 Stable crystalline monohydrates of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo [3.2.1] oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides their preparation and pharmaceutical compositions containing them IL105143A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI920720A IT1254562B (it)	1992-03-26	1992-03-26	Forma cristallina dell'endo-3-etil-2,3-diidro-n-(8-metil-8-azabiciclo (3.2.1) ott-3-il)- 2-oxo-1h-benzimidazolo-1-carbossamide cloridrato
ITMI920723A IT1254565B (it)	1992-03-26	1992-03-26	Forma cristallina dell'endo-2,3-diidro-n-(8 metil-8-azabiciclo-(3.2.1) ott-3-il)-2-oxo-1h-benzimidazolo-1-carbossamide cloridrato

Publications (1)

Publication Number	Publication Date
IL105143A true IL105143A (en)	1996-10-16

Family

ID=26330860

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10514393A IL105143A (en)	1992-03-26	1993-03-24	Stable crystalline monohydrates of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo [3.2.1] oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides their preparation and pharmaceutical compositions containing them

Country Status (27)

Country	Link
US (1)	US5468758A (de)
EP (1)	EP0567767B1 (de)
JP (1)	JP3279707B2 (de)
AT (1)	ATE169016T1 (de)
AU (1)	AU654082B2 (de)
BR (1)	BR1100564A (de)
CA (1)	CA2092510C (de)
CZ (1)	CZ286590B6 (de)
DE (1)	DE69319955T2 (de)
DK (1)	DK0567767T3 (de)
ES (1)	ES2118846T3 (de)
FI (1)	FI113472B (de)
HR (1)	HRP930479B1 (de)
HU (2)	HU211075B (de)
IL (1)	IL105143A (de)
MX (1)	MX9301668A (de)
NO (1)	NO300975B1 (de)
NZ (1)	NZ247234A (de)
PH (1)	PH30413A (de)
PL (1)	PL172890B1 (de)
RU (1)	RU2125054C1 (de)
SG (1)	SG43225A1 (de)
SI (1)	SI9300150B (de)
SK (1)	SK280555B6 (de)
TW (1)	TW385310B (de)
UA (1)	UA37179C2 (de)
UY (2)	UY25939A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69733288T2 (de)	1996-01-17	2006-01-26	Ricoh Co., Ltd.	Fixiergerät für ein Bilderzeugungsgerät
JPH1039679A (ja) *	1996-05-24	1998-02-13	Ricoh Co Ltd	定着装置
PE20001420A1 (es)	1998-12-23	2000-12-18	Pfizer	Moduladores de ccr5
US8697722B2 (en) *	2007-11-02	2014-04-15	Sri International	Nicotinic acetylcholine receptor modulators
WO2011085389A1 (en) *	2010-01-11	2011-07-14	Astraea Therapeutics, Llc	Nicotinic acetylcholine receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4136189A (en) *	1975-09-16	1979-01-23	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T.	2-(5-nitro-furfurylidene)-amino-benzimidoles and fungicidal compositions containing the same
US5223511A (en) *	1987-09-23	1993-06-29	Boehringer Ingelheim Italia S.P.A.	Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1231413B (it) *	1987-09-23	1991-12-04	Angeli Inst Spa	Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
GB9121835D0 (en) *	1991-10-15	1991-11-27	Smithkline Beecham Plc	Pharmaceuticals
DE69319939T2 (de) *	1992-02-04	1999-02-18	Eisai Co., Ltd., Tokio/Tokyo	Aminobenzoesäure Derivate

1993
- 1993-03-11 PH PH45858A patent/PH30413A/en unknown
- 1993-03-19 DE DE69319955T patent/DE69319955T2/de not_active Expired - Lifetime
- 1993-03-19 DK DK93104564T patent/DK0567767T3/da active
- 1993-03-19 AT AT93104564T patent/ATE169016T1/de active
- 1993-03-19 ES ES93104564T patent/ES2118846T3/es not_active Expired - Lifetime
- 1993-03-19 EP EP93104564A patent/EP0567767B1/de not_active Expired - Lifetime
- 1993-03-19 CZ CZ1993443A patent/CZ286590B6/cs not_active IP Right Cessation
- 1993-03-19 SG SG1996005867A patent/SG43225A1/en unknown
- 1993-03-22 SK SK226-93A patent/SK280555B6/sk not_active IP Right Cessation
- 1993-03-23 HR HRMI92A000723A patent/HRP930479B1/xx not_active IP Right Cessation
- 1993-03-24 NZ NZ247234A patent/NZ247234A/en not_active IP Right Cessation
- 1993-03-24 TW TW082102205A patent/TW385310B/zh not_active IP Right Cessation
- 1993-03-24 IL IL10514393A patent/IL105143A/en not_active IP Right Cessation
- 1993-03-24 AU AU35413/93A patent/AU654082B2/en not_active Ceased
- 1993-03-25 NO NO931112A patent/NO300975B1/no not_active IP Right Cessation
- 1993-03-25 JP JP06649293A patent/JP3279707B2/ja not_active Expired - Lifetime
- 1993-03-25 CA CA002092510A patent/CA2092510C/en not_active Expired - Lifetime
- 1993-03-25 MX MX9301668A patent/MX9301668A/es not_active IP Right Cessation
- 1993-03-25 HU HU9300868A patent/HU211075B/hu not_active IP Right Cessation
- 1993-03-25 RU RU93004710A patent/RU2125054C1/ru not_active IP Right Cessation
- 1993-03-25 PL PL93298263A patent/PL172890B1/pl not_active IP Right Cessation
- 1993-03-25 FI FI931329A patent/FI113472B/fi not_active IP Right Cessation
- 1993-03-26 SI SI9300150A patent/SI9300150B/sl not_active IP Right Cessation
- 1993-06-08 UA UA93002686A patent/UA37179C2/uk unknown
1994
- 1994-06-22 US US08/264,104 patent/US5468758A/en not_active Expired - Lifetime
1995
- 1995-06-30 HU HU95P/P00677P patent/HU211131A9/hu unknown
1997
- 1997-05-13 BR BR1100564-5A patent/BR1100564A/pt active IP Right Grant
2000
- 2000-01-17 UY UY25939A patent/UY25939A1/es not_active Application Discontinuation
- 2000-01-17 UY UY25938A patent/UY25938A1/es unknown

Also Published As

Publication number	Publication date
PH30413A (en)	1997-05-09
FI113472B (fi)	2004-04-30
NO931112D0 (no)	1993-03-25
HK1010719A1 (en)	1999-06-25
JP3279707B2 (ja)	2002-04-30
DK0567767T3 (da)	1999-02-01
ATE169016T1 (de)	1998-08-15
FI931329L (fi)	1993-09-27
HRP930479A2 (en)	1995-02-28
PL298263A1 (en)	1994-01-10
CA2092510C (en)	2004-02-03
SK22693A3 (en)	1993-11-10
JPH0673053A (ja)	1994-03-15
NO931112L (no)	1993-09-27
UA37179C2 (uk)	2001-05-15
SI9300150B (sl)	1998-06-30
HU211131A9 (en)	1995-10-30
NO300975B1 (no)	1997-08-25
MX9301668A (es)	1993-09-01
DE69319955T2 (de)	1999-04-15
HU9300868D0 (en)	1993-06-28
AU3541393A (en)	1993-09-30
EP0567767A1 (de)	1993-11-03
DE69319955D1 (de)	1998-09-03
SI9300150A (en)	1993-09-30
NZ247234A (en)	1995-12-21
SG43225A1 (en)	1997-10-17
CZ44393A3 (en)	1994-01-19
AU654082B2 (en)	1994-10-20
CA2092510A1 (en)	1993-09-27
CZ286590B6 (cs)	2000-05-17
HRP930479B1 (en)	1999-10-31
BR1100564A (pt)	2000-06-27
HU211075B (en)	1995-10-30
FI931329A0 (fi)	1993-03-25
SK280555B6 (sk)	2000-03-13
US5468758A (en)	1995-11-21
ES2118846T3 (es)	1998-10-01
UY25938A1 (es)	2000-09-29
HUT63846A (en)	1993-10-28
RU2125054C1 (ru)	1999-01-20
PL172890B1 (pl)	1997-12-31
EP0567767B1 (de)	1998-07-29
TW385310B (en)	2000-03-21
UY25939A1 (es)	2001-08-27

Legal Events

Date	Code	Title
1997-03-18	FF	Patent granted
1997-07-13	KB	Patent renewed
1999-08-17	KB	Patent renewed
2001-06-14	RH	Patent void
2003-06-24	KB	Patent renewed
2013-11-28	EXP	Patent expired

Publication	Publication Date	Title
JP7644027B2 (ja)	2025-03-11	Ｂｔｋ阻害剤の結晶形態
EP1765379A2 (de)	2007-03-28	Pharmazeutische ko-kristallzusammensetzungen und relevante anwendungsverfahren
EP3183253B1 (de)	2018-06-27	Salz von (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitril mit benzolsulfonsäure
JP2016006063A (ja)	2016-01-14	サクサグリプチンの結晶形態
JP2017193561A (ja)	2017-10-26	３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態
RU2193560C2 (ru)	2002-11-27	Новая соль
IL105143A (en)	1996-10-16	Stable crystalline monohydrates of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo [3.2.1] oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides their preparation and pharmaceutical compositions containing them
JP2013529224A (ja)	2013-07-18	結晶性エザチオスタット塩酸塩非溶媒和物
CN104159584A (zh)	2014-11-19	阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
US8361971B2 (en)	2013-01-29	Tablet formulation of ezatiostat
KR100256148B1 (ko)	2000-05-15	결정 형태의 엔도-2,3-디하이드로-n-(8-메틸-8-아자비사이클로(3.2.1)옥트-3-일)-2-옥트-1h-벤즈이미다졸-1-카복스아미드 하이드로클로라이드 1수화물 및 엔도-3-에틸-2,3-디하이드로-n-(8-메틸-8-아자비시클로(3.2.1)옥트-3-일)-2옥소-1h-벤즈이미다졸-1-카복스아미드 하이드로클로라이드 1수화물
CN113227069B (zh)	2024-11-05	一种化合物的晶型、其组合物及使用方法
HK1010719B (en)	2000-05-05	Crystalline forms of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo (3.2.1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamide hydrochloride monohydrate and of endo-3-ethyl-2,3-dihydro-n-(8-methyl-8-azabicyclo (3.2.1) oct-3-yl)-2-oxo-1 h-benzimidazole-1-carboxamide hydrochloride monohydrate as 5-ht antagonists
EA045430B1 (ru)	2023-11-24	Композиция, содержащая гидрат безилата левамлодипина, и способ ее получения
RU2178789C2 (ru)	2002-01-27	Новые полиморфные формы дигидрохлорида лесопитрона и их гидратные формы, способы получения и композиции на их основе
HK40105022B (en)	2024-10-25	Crystalline hydrobromide salt of 5-meo-dmt
HK40105022A (en)	2024-08-02	Crystalline hydrobromide salt of 5-meo-dmt
WO2019053491A1 (en)	2019-03-21	CRYSTALLINE BENIDIPINE HCL SOLID FORMS AND PROCESSES FOR PREPARING THE SAME